Payment overview · 2025
General Payments
$1,536.06
64 reported records · 14 companies
Healthcare provider profile · identity verified
Constantine Vafidis, MD
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSTON, RI · NPI 1467683227
Verified facts
What the public records show
CMS Open Payments records show Constantine Vafidis, MD received $1,536.06 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $395.06 | 25.7% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $362.50 | 23.6% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $240.03 | 15.6% | 9 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $169.13 | 11.0% | 6 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.81 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.27 | 5.2% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $41.20 | 2.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.69 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.02 | 1.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.57 | 1.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.28 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.26 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.42 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.82 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,536.06 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $267.41 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $243.41 | 13 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $169.13 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $154.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $150.07 | 7 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $108.81 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.27 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.63 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $49.23 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $41.20 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.76 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 110 |
| Prednisone | Prednisone | 301 | 244 |
| Azithromycin | Azithromycin | 214 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 69 |
| Losartan Potassium | Losartan Potassium | 196 | 67 |
| Lisinopril | Lisinopril | 166 | 56 |
| Omeprazole | Omeprazole | 161 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 67 |
| Methylprednisolone | Methylprednisolone | 129 | 112 |
| Alprazolam | Alprazolam | 126 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 121 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 36 |
| Gabapentin | Gabapentin | 99 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 26 |
| Montelukast Sodium | Montelukast Sodium | 88 | 32 |
| Clonazepam | Clonazepam | 83 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 14 |
| Metformin Hcl Er | Metformin Hcl | 71 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 68 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 43 |
| Metformin Hcl | Metformin Hcl | 64 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Furosemide | Furosemide | 60 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 14 |
| Cephalexin | Cephalexin | 58 | 55 |
| Eliquis | Apixaban | 58 | 16 |
| Lorazepam | Lorazepam | 58 | 14 |
| Ibuprofen | Ibuprofen | 57 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 36 |
| Famotidine | Famotidine | 51 | 14 |
| Meloxicam | Meloxicam | 51 | 38 |
| Sertraline Hcl | Sertraline Hcl | 51 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 43 |
| Mirtazapine | Mirtazapine | 47 | 13 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 37 |
| Ozempic | Semaglutide | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 27 |
| Meclizine Hcl | Meclizine Hcl | 40 | 25 |
| Naproxen | Naproxen | 40 | 24 |
| Amoxicillin | Amoxicillin | 39 | 36 |
| Fluconazole | Fluconazole | 38 | 29 |
| Trazodone Hcl | Trazodone Hcl | 38 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 18 |
| Allopurinol | Allopurinol | 36 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Mupirocin | Mupirocin | 35 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 29 | 27 |
| Baclofen | Baclofen | 28 | 12 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Glipizide | Glipizide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Ondansetron Odt | Ondansetron | 20 | 18 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 14 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Mesalamine | Mesalamine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,536.06 · 64 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, NURTEC ODT, NUZYRA, PURIFIED CORTROPHIN GEL, QULIPTA, SKYCLARYS, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, VYNDAQEL, ZAVZPRET, ZENPEP, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error